<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        16-475-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VECTIBIX 20MG/ML CONC. SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANITUMUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2323.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="AMGEN MANUFACTURING LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            AMGEN MANUFACTURING LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AMGEN EUROPE B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XC08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vectibix is used in the treatment of metastatic colorectal cancer (cancer of the bowel) for adult patients with a certain type of tumour known as a &ldquo;Wild-type <em>RAS</em> tumour&rdquo;. Vectibix is used alone or in combination with other anti‑cancer medicines.</p><p>Vectibix contains the active substance panitumumab, which belongs to a group of medicines called monoclonal antibodies. Monoclonal antibodies are proteins, which specifically recognise and attach (bind) to other unique proteins in the body.</p><p>Panitumumab recognises and binds specifically to a protein known as epidermal growth factor receptor (EGFR), which is found on the surface of some cancer cells. When growth factors (other body proteins) attach to the EGFR, the cancer cell is stimulated to grow and divide. Panitumumab binds onto the EGFR and prevents the cancer cell from receiving the messages it needs for growth and division.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Vectibix</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to panitumumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have previously had or have evidence of interstitial pneumonitis (swelling of the lungs causing coughing and difficulty breathing) or pulmonary fibrosis (scarring and thickening in the lungs with shortness of breath).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with oxaliplatin-based chemotherapy, if your <em>RAS</em> test shows that you have mutant <em>RAS</em> tumour, or if your <em>RAS</em> tumour status is unknown. Please consult your doctor if you are unsure of your <em>RAS</em> tumour status.</p><p><strong>Warnings and precautions</strong></p><p>You may experience skin reactions or severe swelling and tissue damage, if these worsen or become intolerable please tell your doctor or nurse immediately. If you experience a severe skin reaction, your doctor may recommend an adjustment of the dose of Vectibix. If you develop a severe infection or fever as a result of skin reactions, your doctor may stop your treatment with Vectibix.</p><p>It is recommended that you limit sun exposure whilst receiving Vectibix and if you are experiencing skin reactions as sunlight can worsen these. Wear sunscreen and a hat if you are going to be exposed to sunlight. Your doctor may ask you to use a moisturiser, sun screen (SPF&nbsp;&gt;&nbsp;15), topical steroid, and/or oral antibiotics which may help in the management of skin toxicities that can be associated with the use of Vectibix.</p><p>Your doctor will check your blood levels of several substances such as magnesium, calcium and potassium in your blood before you start Vectibix treatment. Your doctor will also check your blood levels of magnesium and calcium periodically during your treatment, and for up to 8&nbsp;weeks after you have finished your treatment. If these levels are too low, your doctor may prescribe you appropriate supplements.</p><p>If you experience severe diarrhoea please tell your doctor or nurse since you may lose a lot of water from your body (become dehydrated) and this could damage your kidneys.</p><p>Tell your doctor if you use contact lenses and/or have a history of eye problems such as severe dry eye, inflammation of the front part of the eye (cornea) or ulcers involving the front part of the eye.</p><p>If you develop acute or worsening redness and pain in the eye, increased eye watering, blurred vision and/or sensitivity to light, please tell your doctor or nurse immediately as you may need urgent treatment (see &ldquo;Possible side effects&rdquo; below).</p><p>Based on your age (older than 65&nbsp;years) or general health, your doctor will discuss with you your ability to tolerate taking Vectibix with your chemotherapy treatment.</p><p>&nbsp;</p><p><strong>Other medicines and Vectibix</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal medicines.</p><p>Vectibix should not be used in combination with bevacizumab (another monoclonal antibody used in cancer of the bowel) or with a chemotherapy combination known as &ldquo;IFL&rdquo;.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Vectibix has not been tested in pregnant women. It is important to tell your doctor if you are pregnant; think you may be pregnant; or plan to get pregnant. Vectibix could affect your unborn baby or ability to stay pregnant.</p><p>If you are a woman of child bearing potential, you should use effective methods of contraception during treatment with Vectibix and for 2&nbsp;months after the last dose.</p><p>It is not recommended to breast-feed your baby during treatment with Vectibix and for 2&nbsp;months after the last dose. It is important to tell your doctor if you plan to breast-feed.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>You should speak with your doctor before driving or using machines, as some side effects may impair your ability to do so safely.</p><p>&nbsp;</p><p><strong>Vectibix contains sodium</strong></p><p>This medicine contains 3.45&nbsp;mg sodium (main component of cooking/table salt) in each mL unit. This is equivalent to 0. 17% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vectibix will be administered in a healthcare facility under the supervision of a doctor experienced in the use of anti-cancer medicines.</p><p>Vectibix is administered intravenously (into a vein) with an infusion pump (a device that gives a slow injection).</p><p>The recommended dose of Vectibix is 6&nbsp;mg/kg (milligrams per kilogram of body weight) given once every two weeks. The treatment will usually be given over a period of approximately 60&nbsp;minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The most serious side effects and main side effects for Vectibix are listed below:</p><p><strong>Infusion reactions</strong></p><p>During or following treatment you may experience an infusion reaction. These can be mild or moderate (likely to occur in approximately 5&nbsp;out of 100&nbsp;people who take Vectibix), or severe (likely to occur in 1&nbsp;out of 100&nbsp;people who take Vectibix). Symptoms may include headache, rashes, itching or hives, flushing, swelling (face, lips, mouth, around the eyes, and throat area), rapid and irregular heartbeat, fast pulse, sweating, nausea, vomiting, dizziness, difficulty breathing or swallowing, or a decrease in blood pressure that may be severe or life-threatening and, very rarely, may lead to death. If you experience any of these symptoms, you should notify your doctor immediately. Your doctor may decide to reduce the rate of your infusion or discontinue your treatment with Vectibix.</p><p>&nbsp;</p><p><strong>Allergic reactions</strong></p><p>Very rarely, serious allergic (hypersensitivity) reactions involving symptoms similar to an infusion reaction (see &ldquo;Infusion reactions&rdquo;) have occurred more than 24&nbsp;hours after treatment and resulted in a fatal outcome. Seek medical attention immediately if you experience symptoms of an allergic reaction to Vectibix, including but not limited to difficulty breathing, chest tightness, a sensation of choking, dizziness, or fainting.</p><p>&nbsp;</p><p><strong>Skin reactions</strong></p><p>Skin-related reactions are likely to occur in approximately 94&nbsp;out of 100&nbsp;people who take Vectibix and are usually mild to moderate. The skin rash commonly resembles acne and often involves the face, upper chest and back, but can affect any area of the body. Some rashes have been associated with redness, itching and flaking of the skin which can become severe. In some cases, it may cause infected sores requiring medical and/or surgical treatment, or cause severe skin infections that in rare cases could be fatal. In rare cases patients may experience blistering of the skin, mouth, eyes and genitals, which may indicate a severe skin reaction called &ldquo;Stevens-Johnson syndrome&rdquo; or blistering of the skin, which may indicate a severe skin reaction called &ldquo;toxic epidermal necrolysis&rdquo;. If you experience blistering, you should notify your doctor immediately. Prolonged exposure to the sun can make the rash worse. Also, dry skin, fissures (cracks in the skin) on the fingers or toes, fingernail bed or toenail bed infection (paronychia) or inflammation has been reported. Once treatment is withheld or discontinued, the skin reactions will generally resolve. Your doctor may decide to treat the rash, adjust the dose or discontinue your treatment with Vectibix.</p><p>&nbsp;</p><p>Other side effects include:</p><p><strong>Very common:</strong> may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low red blood cell numbers (anaemia); low potassium levels in the blood (hypokalaemia); low magnesium levels in the blood (hypomagnesaemia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye inflammation (conjunctivitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; local or widespread rash which may be bumpy (with or without spots), itchy, red or flaky;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss (alopecia); mouth ulcers and cold sores (stomatitis); inflammation of the mouth (mucosal inflammation);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea; nausea; vomiting; abdominal pain; constipation; decreased appetite; decreased weight;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; extreme tiredness (fatigue); fever or high temperature (pyrexia); lack or loss of strength (asthenia); accumulation of fluid in the extremities (oedema peripheral);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inability to sleep (insomnia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough; dyspnoea (breathing difficulties).</p><p>&nbsp;</p><p><strong>Common: </strong>may affect up to&nbsp;1 in 10&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low white blood numbers (leucopenia); low calcium levels in the blood (hypocalcaemia); low phosphates in the blood (hypophosphataemia); high glucose in the blood (hyperglycaemia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; growth of eyelashes; flow of tears (lacrimation increased); redness of the eye (ocular hyperaemia); dry eye; itchy eyes (eye pruritus); eye irritation; eyelid inflammation (blepharitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin ulcer; scab; excess hair growth (hypertrichosis); redness and swelling of palms of hands or soles of feet (hand-foot syndrome); excess sweating (hyperhidrosis); skin reaction (dermatitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; spreading infection below the skin (cellulitis); hair follicle inflammation (folliculitis); localised infection; skin rash with pus-filled blisters (rash pustular); urinary tract infection;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nail disorder; breaking of the nails (onychoclasis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dehydration;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth; indigestion (dyspepsia); rectal bleeding (rectal haemorrhage); lip inflammation (cheilitis); heartburn (gastroesophageal reflux);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain; pain; chills; pain in the extremity; immune reaction (hypersensitivity); rapid heart rate (tachycardia);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in the lung (pulmonary embolism) the symptoms of which may be sudden onset of shortness of breath or chest pain; nose bleed (epistaxis); blood clot in a deep vein (deep vein thrombosis); high blood pressure (hypertension); flushing;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache; dizziness; anxiety.</p><p>&nbsp;</p><p><strong>Uncommon:</strong> may affect up to&nbsp;1 in 100&nbsp;people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blue colouration of the skin and mucous membranes (cyanosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin cell death (skin necrosis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reaction with blistering of the skin, mouth, eyes and genitals (Stevens‑Johnson syndrome);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin reaction with blistering of the skin (toxic epidermal necrolysis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a serious condition of ulceration of the front part of the eye (cornea) requiring urgent treatment (ulcerative keratitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the front part of the eye (cornea) (keratitis);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eyelid irritation; chapped lips and/or dry lips; eye infection; eyelid infection; nasal dryness; loosening of the nails (onycholysis); ingrowing nail; excessive hair growth (hirsutism);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the lungs (interstitial lung disease).</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vectibix will be stored in the healthcare facility where it is used.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Store in the original carton in order to protect from light.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each mL of concentrate contains 20&nbsp;mg panitumumab. Each vial contains either 100&nbsp;mg of panitumumab in 5&nbsp;mL, or 400&nbsp;mg of panitumumab in 20&nbsp;mL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in each 5 mL: sodium chloride (29 mg), sodium acetate trihydrate (34 mg), acetic acid glacial (for pH adjustment to target 5.8) and water for injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in each 20 mL: sodium chloride (117 mg), sodium acetate trihydrate (136 mg), acetic acid glacial (for pH adjustment to target 5.8) and water for injections.</p><p>See section 2 &ldquo;Vectibix contains sodium&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vectibix is a colorless liquid that may contain visible particles and is supplied in a glass vial. Each pack contains one vial.
	
	Not all presentations may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Site of Manufacture of the Drug Product:</strong></p><p>Amgen Manufacturing Limited</p><p>State Road 31</p><p>Kilometer 24.6</p><p>Juncos 00777 - 4060</p><p>Puerto Rico</p><p>USA</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>Amgen Europe B.V.</p><p>Minervum 7061</p><p>4817 ZK Breda</p><p>The Netherlands</p><p>&nbsp;</p><p>For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in October 2021.
	
	Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يتم استخدام فكتبيكس في علاج سرطان القولون والمستقيم النقيلي (سرطان الأمعاء) لدى المرضى البالغين المصابين بنوع معين من الورم المعروف باسم &quot;ورم ناتج عن جين <em>RAS</em> ذي النوع الجامح&quot;. ويستخدم فكتبيكس بمفرده أو بالاشتراك مع أدوية أخرى مضادة للسرطان.</p><p dir="RTL">يحتوي فكتبيكس على المادة الفعالة بانيتوموماب، والتي تنتمي إلى مجموعة من الأدوية يطلق عليها الأجسام أحادية النسيلة. وتعد هذه الأجسام بروتينات تتعرف تحديدا على بروتينات استثنائية أخرى في الجسم وترتبط بها.</p><p dir="RTL">و تتعرف مادة البانيتوموماب على بروتين يعرف باسم مستقبل عامل النمو البشروي (EGFR) وترتبط به، وهو بروتين موجود على سطح بعض الخلايا السرطانية. وعندما ترتبط عوامل النمو (بروتينات الجسم الأخرى) ببروتين EGFR، يتم تحفيز الخلية السرطانية على النمو والانقسام. فيعمل البانيتوموماب على الارتباط ببروتين EGFR ويمنع الخلية السرطانية من تلقي الرسائل التي تحتاجها للنمو والانقسام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تستخدم فكتبيكس في الحالات التالية</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية للبانيتوموماب أو أي مكونات أخرى من هذا الدواء (المذكورة في المقطع&nbsp;٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك فيما مضى أو إذا كان لديك دليل على الإصابة بالتهاب رئوي خلالي (تورم في الرئتين يسبب سعال وصعوبة في التنفس) أو الإصابة بتليف رئوي (تندب وزيادة سماكة الرئتين مع ضيق في التنفس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالتزامن مع العلاج الكيميائي القائم على استخدام أوكزاليبلاتين، إذا كان الاختبار الخاص بجين <em>RAS</em> يشير إلى أن لديك ورم ناتج عن جين <em>RAS</em> المتحول، أو إذا كانت حالة الورم الناتج عن RAS ليست معروفة. ويرجى استشارة طبيبك إذا لم تكن متأكدا بشأن حالة الورم الناتج عن <em>RAS&rlm;</em>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><strong><s>&nbsp;</s></strong></p><p dir="RTL">قد تتعرض إلى تفاعلات جلدية أو تورم شديد وتلف الأنسجة، فإذا ازداد الأمر سوءا أو أصبح غير محتمل، يرجى إخبار طبيبك أو ممرضتك على الفور. وإذا تعرضت لتفاعل شديد بالجلد، قد يوصيك الطبيب بضبط جرعة فكتبيكس. في حالة الإصابة بعدوى حادة أو الحمى بسبب تفاعل جلدي، فقد يوقف طبيبك العلاج بفكتبيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يوصى بالحد من التعرض للشمس إذا كنت تتلقى فكتبيكس أو إذا كنت تتعرض لتفاعلات بالجلد لأن ضوء الشمس قد يجعل الأمر أكثر سوءا. ولذلك ضع واقيا من الشمس وارتد قبعة إذا كنت ستتعرض لضوء الشمس. وقد يطلب منك الطبيب أن تستخدم كريما مرطبا، أو واقيا من الشمس (بمعامل حماية من الشمس &nbsp;&lt;&nbsp;SPF١٥)، أو كورتيزون موضعي، أو مضادات حيوية، أو جميعها معا مما قد يساعد في معالجة تسمم الجلد الذي قد ينتج عن استخدام فكتبيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وسوف يتحقق طبيبك من النسبة الدموية لعدد من المواد مثل الماغنيسيوم، الكالسيوم والبوتاسيوم قبل بدء العلاج بفكتبيكس. وسوف يتحقق طبيبك أيضا من النسبة الدموية للماغنيسيوم والكالسيوم بصورة دورية أثناء فترة العلاج ولمدة تصل إلى ٨&nbsp;أسابيع بعد انتهائك من العلاج. وإذا كانت هذه المستويات منخفضة جدا، قد يصف لك طبيبك المكملات المناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وإذا تعرضت لإسهال شديد، يرجى إخبار طبيبك أو ممرضتك لأنك قد تفقد كمية كبيرة من المياه من جسمك (وتصاب بالجفاف) وقد يؤدي ذلك إلى الإضرار بالكلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم عدسات لاصقة و/أو إذا كان لديك سوابق مرضية بوجود مشاكل في العين، وذلك مثل جفاف شديد بالعين، التهاب الجزء الأمامي للعين (القرنية) أو قرح بالجزء الأمامي للعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وإذا ظهرت لديك أعراض احمرار أو ألم بالعين بصورة حادة أو بصورة تزداد سوءا، أو زيادة في مياه العين، أو عدم وضوح الرؤية أو حساسية من الضوء، أو جميعهم معا، يرجى إخبار طبيبك أو ممرضتك على الفور لأنك قد تحتاج إلى تلقي العلاج بشكل عاجل (انظر &quot;الآثار الجانبية المحتملة&quot; أدناه).</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيناقش معك الطبيب مدى قدرتك على تحمل فكتبيكس بالتزامن مع العلاج الكيميائي الخاص بك، وذلك وفقا لعمرك (أكثر من ٦٥ عاما) أو حالتك الصحية بوجه عام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وفكتبيكس</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يرجى إخبار الطبيب أو الصيدلي الخاص بك إذا كنت تتناول أو قد تناولت مؤخرا أدوية أخرى تتضمن أدوية قد حصلت عليها دون وصفة طبية أو أدوية عشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ولا يجب استخدام فكتبيكس بالتزامن مع بيفاسيزوماب (إحدى الأجسام أحادية النسيلة الأخرى التي تستخدم في حالات سرطان الأمعاء) أو مع العلاج الكيميائي المعروف باسم &quot;IFL&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يتم اختبار فكتبيكس لدى السيدات الحوامل. فمن المهم أن تخبري الطبيب إذا كنت حاملا، أو تعتقدين أنك حاملا، أو تخططين للحمل. فقد يؤثر فكتبيكس على الطفل الذي تحملينه أو قدرتك على الحفاظ على الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وإذا كنت من السيدات في سن الإنجاب، فعليك استخدام وسائل فعالة لمنع الحمل أثناء العلاج بفكتبيكس ولمدة شهرين بعد الجرعة الأخيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ولا يوصى بإرضاع طفلك أثناء فترة العلاج بفكتبيكس ولمدة شهرين بعد الجرعة الأخيرة. ومن المهم أن تخبري طبيبك إذا كنت تخططين للإرضاع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وينصح باستشارة الطبيب أو الصيدلي الخاص بك قبل تناول أي دواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>قيادة السيارات واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب أن تتحدث إلى طبيبك قبل القيادة أو استخدام الآلات لأن بعض الآثار الجانبية للدواء قد تعيق قدرتك على القيام بذلك بشكل آمن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فكتبيكس على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على ٣٫٤٥&nbsp;مجم من الصوديوم (المكون الأساسي في ملح الطهو/الطعام) في كل وحدة مل. يعادل هذا ٠٫۱٧٪ من الجرعة الغذائية اليومية القصوى الموصى بها من الصوديوم لشخص بالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم إعطاء فكتبيكس في منشأة رعاية صحية تحت إشراف طبيب ذو خبرة في استخدام الأدوية المضادة للسرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء فكتبيكس عن طريق الوريد (عن طريق الحقن داخل الوريد) باستخدام مضخة تسريب (جهاز للحقن البطئ).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن الجرعة الموصى بها من فكتبيكس هي ٦&nbsp;مجم/كجم (مليجرامات لكل كيلوجرام من وزن الجسم) مرة واحدة كل أسبوعين. وعادة ما يتم إعطاء العلاج خلال فترة ٦٠ دقيقة تقريبا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثارا جانبية على الرغم من عدم حصولها لدى كل الأشخاص.</p><p dir="RTL">وقد تم إدراج الآثار الجانبية الأكثر خطورة والآثار الجانبية الرئيسية أدناه:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات التسريب</strong></p><p dir="RTL">قد تتعرض لتفاعل التسريب أثناء أو بعد العلاج. ويمكن أن تكون هذه التفاعلات طفيفة أو متوسطة (من المحتمل حدوثها لدى نحو ٥&nbsp;أشخاص عن ١٠٠&nbsp;شخص ممن يتناولون فكتبيكس)، أو حادة (من المحتمل حدوثها لدى ١ عن ١٠٠&nbsp;شخص ممن يتناولون فكتبيكس). وقد تتضمن الأعراض صداع، وطفح جلدي، وحكة أو حساسية، وبيغ، وتورم (الوجه، الشفاه، الفم، ما حول العين، ومنطقة الحلق)، وضربات قلب سريعة وغير منتظمة، ونبض سريع،&nbsp; تعرق، وغثيان،&nbsp; قيء، ودوار، وصعوبة التنفس أو البلع، أو انخفاض في ضغط الدم الذي قد يكون حادا أو يهدد الحياة أو قد يؤدي في حالات نادرة جدا إلى الوفاة. فإذا تعرضت لأي من هذه الأعراض، يجب أن تبلغ طبيبك على الفور. وقد يقرر الطبيب تقليل معدل التسريب أو إيقاف العلاج بفكتبيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات أرجية</strong></p><p dir="RTL">لقد حدثت في حالات نادرة جدا تفاعلات أرجية (فرط حساسية) خطيرة تتضمن أعراض مماثلة لتفاعل التسريب (انظر &quot;تفاعلات التسريب&quot;)، وكان ذلك بعد أكثر من ٢٤&nbsp;ساعة من العلاج وأدى إلى نتيجة مميتة. التمس العناية الطبية على الفور إذا تعرضت لأعراض تفاعل أرجي لفكتبيكس، بما في ذلك لا للحصر صعوبة في التنفس، وضيق الصدر، والإحساس بالاختناق، والدوار، أو الإغماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الجلد</strong></p><p dir="RTL">من المحتمل أن تحدث تفاعلات الجلد لدى نحو ٩٤&nbsp;شخصا من بين ١٠٠&nbsp;شخص ممن يتناولون فكتبيكس وهي عادة ما تكون طفيفة إلى متوسطة. وكثيرا ما يشبه الطفح الجلدي حب الشباب ويصيب الوجه، والجزء العلوي من الصدر والظهر، ولكنه يمكن أن يصيب أي منطقة من الجسم. وقد ارتبطت بعض حالات الطفح الجلدي بحدوث احمرار، وحكة، وتقشر الجلد وهي أعراض يمكن أن تصبح حادة. وقد يؤدي الطفح الجلدي في بعض الحالات إلى قروح مصابة بعدوى مما يقتضي العلاج الدوائي أو الجراحي أو كليهما، أو قد يؤدي الطفح الجلدي إلى عدوى حادة بالجلد يمكن أن تكون مميتة في حالات نادرة. في حالات نادرة قد يواجه المرضى ظهور تقرحات في الجلد والفم والعينين والأعضاء التناسلية، والتي قد تشير إلى وجود رد فعل جلدي شديد يسمى &quot;متلازمة ستيفنز جونسون&quot; أو ظهور تقرحات في الجلد، والتي قد تشير إلى وجود رد فعل جلدي شديد يسمى &quot;انحلال البشرة السام&quot;. إذا واجهت ظهور تقرحات، يجب اخطار الطبيب فورا. وقد يؤدي التعرض للشمس لفترات طويلة إلى جعل الطفح الجلدي أكثر سوءا. وقد تم أيضا تسجيل حالات جفاف الجلد، والشقوق (شقوق بالجلد) في أصابع اليدين والقدمين، وعدوى سرير الظفر بأصابع اليدين أو عدوى سرير الظفر بأصابع القدمين (الداحس) أو التهابها. وما إن يتم سحب العلاج أو إيقافه، ستنتهي تفاعلات الجلد بوجه عام. وقد يقرر الطبيب علاج الطفح الجلدي أو ضبط جرعة فكتبيكس أو إيقاف العلاج بفكتبيكس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتشمل الآثار الجانبية الأخرى:</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جدا: </strong>قد تصيب أكثر من ١ عن١٠&nbsp;أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد كرات الدم الحمراء (فقر الدم)؛ انخفاض نسبة البوتاسيوم في الدم (نقص البوتاسيوم)؛ انخفاض نسبة الماغنيسيوم في الدم (نقص الماغنيسيوم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين (التهاب الملتحمة)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي موضعي أو عام على شكل تحاديب (مع أو من دون بقع)، مصحوب بحكة، أو احمرار أو تقشر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر (ثعلبة)؛ تقرحات الفم والقروح الباردة (التهاب الفم)؛ والتهاب الفم (التهاب الغشاء المخاطي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال؛ غثيان؛ قيء؛ آلام البطن؛ إمساك؛ نقص الشهية ؛ ونقص الوزن؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب شديد (إرهاق)؛ سخونة أو ارتفاع درجة الحرارة (حمى)؛ نقص أو فقدان القوة البدنية (وهن)؛ وتراكم السوائل في الأطراف (وذمة طرفية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام الظهر؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على النوم (أرق)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال؛ وضيق التنفس (صعوبة التنفس).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الشائعة: </strong>قد تصيب إلى حدود ١ عن ١٠&nbsp;شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص عدد كريات الدم البيضاء (نقص كريات الدم البيضاء)؛ انخفاض نسبة الكالسيوم في الدم (نقص الكالسيوم)؛ انخفاض نسبة الفوسفات في الدم (نقص الفوسفات)؛ وارتفاع نسبة السكر في الدم (فرط سكر الدم)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نمو رموش العين؛ زيادة الدموع (زيادة الدمعان)؛ احمرار العين (تبيغ العين)؛ جفاف العين؛ شعور بالرغبة في حك العين (حكة بالعين)؛ تهيج العين؛ والتهاب جفون العين (التهاب الجفن)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح جلدي؛ جرب؛ زيادة نمو الشعر (فرط نمو الشعر)؛ احمرار وتورم راحة اليدين أو باطن القدمين (متلازمة اليد والقدم)؛ التعرق الزائد (فرط التعرق)؛ رد فعل الجلد (التهاب الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى منتشرة تحت الجلد (التهاب النسيج الضام الرخوي الخلالي)؛ التهاب بصيلات الشعر (التهاب البصيلات)؛ عدوى موضعية؛ وطفح جلدي مع بثور يملؤها القيح (طفح تقيحي)؛ التهاب المسالك البولية؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الأظافر؛ وتكسر الأظافر (تقصف الأظافر)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم؛ صعوبة الهضم (عسر الهضم)؛ حدوث نزيف من المستقيم (نزف المستقيم)؛ التهاب بالشفاه (التهاب الشفاه)؛ وحرقة المعدة (ارتجاع معدي مريئي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالصدر؛ ألم؛ رعدة؛ ألم بالأطراف؛ تفاعل مناعة (فرط حساسية)؛ وسرعة معدل ضربات القلب (تسرع القلب)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية بالرئة (انسداد رئوي) التي قد تكون أعراضها ظهور مفاجئ لضيق في التنفس أو ألم في الصدر؛ نزيف من الأنف (رعاف)؛ جلطة دموية بالأوردة العميقة (تجلط الأوردة العميقة)؛ وارتفاع ضغط الدم (فرط الضغط)؛ وبيغ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع؛ دوار؛ وقلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة:</strong> قد تصيب إلى حدود ١ عن١٠٠&nbsp;شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زرقة لون الجلد والأغشية المخاطية (زراق)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت خلايا الجلد (نخر الجلد)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل جلدي شديد مع تقرحات في الجلد والفم والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل جلدي شديد مع تقرحات في الجلد (انحلال البشرة السام)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة خطيرة من تقرح الجزء الأمامي من العين (القرنية) تتطلب علاجًا عاجلاً (التهاب القرنية التقرحي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجزء الأمامي من العين (القرنية) (التهاب القرنية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج الجفون؛ تشقق الشفاه و/أو الشفاه الجافة؛ عدوى العين؛ عدوى الجفون؛ جفاف الأنف؛ ارتخاء الأظافر (انفكاك الظفر)؛ ظفر ناشب؛ ونمو الشعر المفرط (الشعرانية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين (داء الرئة الخلالي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، يرجى إبلاغ طبيبك أو الممرضة. ويشمل ذلك أي آثار جانبية غير مدرجة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك أن تساعد في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم تخزين فكتبيكس في منشأة الرعاية الصحية التي يتم استخدامه بها.</p><p dir="RTL">يحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ في الثلاجة (٢&deg;م&nbsp;‑&nbsp;٨&deg;م).</p><p dir="RTL">لا يتم تجميده.</p><p dir="RTL">ويحفظ في العبوة الأصلية لحمايته من الضوء.</p><p dir="RTL">لا يتم استخدام هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على البطاقة اللاصقة والعبوة بعد كلمة &quot;انتهاء الصلاحية&quot; &quot;EXP&lrm;&quot;. ويشير تاريخ انتهاء الصلاحية إلى آخر يوم من هذا الشهر.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. واسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد في حاجة إلى استخدامها. فهذه الإجراءات من شأنها الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>عما يحتوي فكتبيكس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي كل مل من السائل المركز على ٢٠&nbsp;مجم من البانيتوموماب. و تحتوي كل قنينة على ١٠٠مجم من البانيتوموماب في ٥&nbsp;مل أو ٤٠٠&nbsp;مجم من البانيتوموماب في٢٠&nbsp;مل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في كل ٥ مل: &nbsp;كلوريد الصوديوم (٢٩مجم)، ثلاثي هيدرات اسيتات الصوديوم (٣٤مجم)، حمض الخليك الجليدي (لتعديلPH &nbsp;لاستهداف ٥٫٨) و ماء للحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في كل ٢٠ مل: &nbsp;كلوريد الصوديوم (١١٧مجم)، ثلاثي هيدرات اسيتات الصوديوم (١٣٦مجم)، حمض الخليك الجليدي (لتعديلPH &nbsp;لاستهداف ٥٫٨) و ماء للحقن.</p><p dir="RTL">&nbsp;انظر&nbsp;القسم&nbsp;٢ &quot;يحتوي فكتبيكس على الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">فكتبيكس هوعبارة عن سائل عديم اللون يحتوي على جزيئات مرئية، ويتوفر في شكل قنينة زجاجية. وتحتوي كل عبوة على قنينة واحدة.</p><p dir="RTL">قد لا يتم تسويق جميع الأشكال الصيدلانية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موقع التصنیع الأولي:</strong></p><p dir="RTL">Amgen Manufacturing Limited</p><p dir="RTL">State Road 31</p><p dir="RTL">Kilometer 24.6</p><p dir="RTL">Juncos 00777 - 4060</p><p dir="RTL">Puerto Rico</p><p dir="RTL">الولایات المتحدة الأمریكیة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حامل تفويض التسويق والشركة المصنعة</strong></p><p dir="RTL">.‪Amgen Europe B.V</p><p dir="RTL">Minervum 7061</p><p dir="RTL">4817&nbsp;ZK Breda</p><p dir="RTL">هولندا</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على أي معلومات حول هذا المنتج الدوائي، يرجى الاتصال بالمندوب المحلي لحامل حق التسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	
تم آخر اعتماد لهذه النشرة في اكتوبر ٢٠٢١.
	
	توجد معلومات تفصيلية عن هذا الدواء على الموقع الالكتروني لوكالة الأدوية الأوروبية:
http://www.ema.europa.eu/‎
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vectibix 20 mg/mL concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of concentrate contains 20 mg panitumumab.

Each vial contains either 100 mg of panitumumab in 5 mL, or 400 mg of panitumumab in 20 mL.

When prepared according to the instructions given in section 6.6, the final panitumumab concentration should not exceed 10 mg/mL.

Panitumumab is a fully human monoclonal IgG2 antibody produced in a mammalian cell line (CHO) by recombinant DNA technology. 

Excipient with known effect
Each mL of concentrate contains 0.150 mmol sodium, which is 3.45 mg sodium.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate). 

Colourless, pH 5.6 to 6.0 solution that may contain translucent to white, visible amorphous, proteinaceous panitumumab particles.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vectibix is indicated for the treatment of adult patients with wild-type <em>RAS</em> metastatic colorectal cancer (mCRC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in first-line in combination with FOLFOX or FOLFIRI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in second-line in combination with FOLFIRI for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vectibix treatment should be supervised by a physician experienced in the use of anti-cancer therapy. Evidence of wild-type <em>RAS</em> (<em>KRAS</em> and <em>NRAS</em>) status is required before initiating treatment with</p><p>Vectibix. Mutational status should be determined by an experienced laboratory using validated test methods for detection of <em>KRAS</em> (exons 2, 3, and 4) and <em>NRAS</em> (exons 2, 3, and 4)&nbsp;mutations.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose of Vectibix is 6&nbsp;mg/kg of bodyweight given once every two weeks.</p><p>&nbsp;</p><p>Modification of the dose of Vectibix may be necessary in cases of severe (&ge;&nbsp;grade 3) dermatological reactions as follows:</p><p><img src="data:image/png;base64,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" alt="" width="910" height="416" vspace="0" hspace="0" border="0" style="width:910px;height:416px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><em><u>Special populations</u></em></p><p><strong>&nbsp;</strong></p><p>The safety and efficacy of Vectibix have not been studied in patients with renal or hepatic impairment.</p><p>&nbsp;</p><p>There is no clinical data to support dose adjustments in the elderly.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>&nbsp;</p><p>There is no relevant use of Vectibix in the paediatric population in the indication treatment of colorectal cancer.</p><p>&nbsp;</p><p><u>Method of administration</u><u> </u></p><p>Vectibix must be administered as an intravenous infusion via an infusion pump.</p><p>&nbsp;</p><p>Prior to infusion, Vectibix should be diluted in sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection to a final concentration not to exceed 10&nbsp;mg/mL (for preparation instructions see section&nbsp;6.6).</p><p>Vectibix must be administered using a low protein binding 0.2&nbsp;or 0.22&nbsp;micrometre in-line filter, through a peripheral line or indwelling catheter. The recommended infusion time is approximately 60&nbsp;minutes. If the first infusion is tolerated, then subsequent infusions may be administered over 30 to 60&nbsp;minutes. Doses higher than 1,000&nbsp;mg should be infused over approximately 90&nbsp;minutes (for handling instructions, see section 6.6).</p><p>&nbsp;</p><p>The infusion line should be flushed with sodium chloride solution before and after Vectibix administration to avoid mixing with other medicinal products or intravenous solutions.</p><p>&nbsp;</p><p>A reduction in the rate of infusion of Vectibix may be necessary in cases of infusion-related reactions (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Vectibix must not be administered as an intravenous push or bolus.</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Patients with a history of severe or life-threatening hypersensitivity to the active substance or to any of the excipients listed in section 6.1 (see section 4.4).

Patients with interstitial pneumonitis or pulmonary fibrosis (see section 4.4).

The combination of Vectibix with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant RAS mCRC or for whom RAS mCRC status is unknown (see section 4.4). 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>Dermatologic reactions and soft tissue toxicity</u></p><p>Dermatologic related reactions, a pharmacologic effect observed with epidermal growth factor receptor (EGFR) inhibitors, are experienced with nearly all patients (approximately 94%) treated with Vectibix. Severe (NCI-CTC grade 3) skin reactions were reported in 23% and life-threatening (NCI‑CTC grade 4) skin reactions in &lt;&nbsp;1% of patients who received Vectibix monotherapy and in combination with chemotherapy (n&nbsp;=&nbsp;2,224) (see section 4.8). In a randomised control trial, skin toxicity was severe (NCI-CTC grade&nbsp;3 and higher) in 15% of patients receiving Vectibix monotherapy (n = 229) (see section 4.8). If a patient develops dermatologic reactions that are grade&nbsp;3 (CTCAE v 4.0) or higher, or that are considered intolerable, see the recommendation for dose modification in section&nbsp;4.2.</p><p>In clinical studies, subsequent to the development of severe dermatologic reactions (including stomatitis), infectious complications including sepsis and necrotising fasciitis, in rare cases leading to death, and local abscesses requiring incisions and drainage were reported. Patients who have severe dermatologic reactions or soft tissue toxicity or who develop worsening reactions whilst receiving Vectibix should be monitored for the development of inflammatory or infectious sequelae (including cellulitis and necrotising fasciitis), and appropriate treatment promptly initiated. Life-threatening and fatal infectious complications including necrotising fasciitis and sepsis have been observed in patients treated with Vectibix. Rare cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported in patients treated with Vectibix in the post-marketing setting. Withhold or discontinue Vectibix in the event of dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications.<strong><em> </em></strong></p><p>Treatment and management of dermatologic reactions should be based on severity and may include a moisturiser, sun screen (SPF&nbsp;&gt;&nbsp;15 UVA and UVB), and topical steroid cream (not stronger than 1% hydrocortisone) applied to affected areas, and/or oral antibiotics (e.g. doxycycline). It is also recommended that patients experiencing rash/dermatological toxicities wear sunscreen and hats and limit sun exposure as sunlight can exacerbate any skin reactions that may occur.</p><p>&nbsp;Patients may be advised to apply moisturiser and sunscreen to face, hands, feet, neck, back and chest every morning during treatment, and to apply the topical steroid to face, hands, feet, neck, back and chest every night during treatment.</p><p>&nbsp;</p><p><u>Pulmonary complications</u></p><p>Patients with a history of, or evidence of, interstitial pneumonitis or pulmonary fibrosis were excluded from clinical studies. Cases of interstitial lung disease (ILD), both fatal and non-fatal, have been reported, mainly from the Japanese population. In the event of acute onset or worsening pulmonary symptoms, Vectibix treatment should be interrupted and a prompt investigation of these symptoms should occur. If ILD is diagnosed, Vectibix should be permanently discontinued and the patient should be treated appropriately. In patients with a history of interstitial pneumonitis or pulmonary fibrosis, the benefits of therapy with panitumumab versus the risk of pulmonary complications must be carefully considered.</p><p>&nbsp;</p><p><u>Electrolyte disturbances </u></p><p>Progressively decreasing serum magnesium levels leading to severe (grade 4) hypomagnesaemia have been observed in some patients. Patients should be periodically monitored for hypomagnesaemia and accompanying hypocalcaemia prior to initiating Vectibix treatment, and periodically thereafter for up to 8&nbsp;weeks after the completion of treatment (see section 4.8). Magnesium repletion is recommended, as appropriate.</p><p>Other electrolyte disturbances, including hypokalaemia, have also been observed. Monitoring as above and repletion as appropriate of these electrolytes is also recommended.</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>Across monotherapy and combination mCRC clinical studies (n&nbsp;=&nbsp;2,224), infusion-related reactions (occurring within 24 hours of an infusion) were reported in Vectibix-treated patients, including severe infusion-related reactions (NCI-CTC grade 3 and grade 4).</p><p>In the post-marketing setting, serious infusion-related reactions have been reported, including rare post-marketing reports with a fatal outcome. If a severe or life-threatening reaction occurs during an infusion or at any time post-infusion [e.g. presence of bronchospasm, angioedema, hypotension, need for parenteral treatment, or anaphylaxis], Vectibix should be permanently discontinued (see sections 4.3 and 4.8).</p><p>In patients experiencing a mild or moderate (CTCAE v&nbsp;4.0 grades 1 and 2) infusion-related reaction the infusion rate should be reduced for the duration of that infusion. It is recommended to maintain this lower infusion rate in all subsequent infusions.</p><p>Hypersensitivity reactions occurring more than 24&nbsp;hours after infusion have been reported including a fatal case of angioedema that occurred more than 24&nbsp;hours after the infusion. Patients should be informed of the possibility of a late onset reaction and instructed to contact their physician if symptoms of a hypersensitivity reaction occur.</p><p>&nbsp;</p><p><u>Acute renal failure</u></p><p>Acute renal failure has been observed in patients who develop severe diarrhoea and dehydration. Patients who experience severe diarrhoea should be instructed to consult a healthcare professional urgently.</p><p>&nbsp;</p><p><u>Vectibix in combination with irinotecan, bolus 5-fluorouracil, and leucovorin (IFL) chemotherapy</u></p><p>Patients receiving Vectibix in combination with the IFL regimen [bolus 5-fluorouracil (500&nbsp;mg/m<sup>2</sup>), leucovorin (20&nbsp;mg/m<sup>2</sup>) and irinotecan (125&nbsp;mg/m<sup>2</sup>)] experienced a high incidence of severe diarrhoea (see section 4.8). Therefore administration of Vectibix in combination with IFL should be avoided (see section 4.5).</p><p>&nbsp;</p><p><u>Vectibix in combination with bevacizumab and chemotherapy regimens</u></p><p>Shortened progression-free survival time and increased deaths were observed in the patients receiving Vectibix in combination with bevacizumab and chemotherapy. A greater frequency of pulmonary embolism, infections (predominantly of dermatologic origin), diarrhoea, electrolyte imbalances, nausea, vomiting and dehydration was also observed in the treatment arms using Vectibix in combination with bevacizumab and chemotherapy. Vectibix should not be administered in combination with bevacizumab containing chemotherapy (see sections 4.5 and 5.1).</p><p>&nbsp;</p><p><u>Vectibix in combination with oxaliplatin-based chemotherapy in patients with mutant <em>RAS</em><em> </em>mCRC or for whom <em>RAS</em><em> </em>tumour status is unknown</u></p><p>The combination of Vectibix with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant <em>RAS</em> mCRC or for whom <em>RAS</em> mCRC status is unknown (see sections 4.3 and 5.1).</p><p>A shortened progression-free survival (PFS) and overall survival (OS) time were observed in patients with mutant <em>KRAS </em>(exon&nbsp;2) tumours and additional <em>RAS</em> mutations (<em>KRAS</em> [exons&nbsp;3 and&nbsp;4] or <em>NRAS</em> [exons&nbsp;2, 3, 4]) who received panitumumab in combination with infusional 5‑fluorouracil, leucovorin, and oxaliplatin (FOLFOX) versus FOLFOX alone (see section&nbsp;5.1).</p><p><em>RAS </em>mutational<em> </em>status should be determined using a validated test method by an experienced laboratory (see section 4.2). If Vectibix is to be used in combination with FOLFOX then it is recommended that mutational status be determined by a laboratory that participates in a <em>RAS</em> External Quality Assurance programme or wild-type status be confirmed in a duplicate test.</p><p>&nbsp;</p><p><u>Ocular toxicities</u></p><p>Serious cases of keratitis and ulcerative keratitis, which may lead to corneal perforation, have been reported. Patients presenting with signs and symptoms suggestive of keratitis such as acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye should be referred promptly to an ophthalmology specialist.</p><p>If a diagnosis of ulcerative keratitis is confirmed, treatment with Vectibix should be interrupted or discontinued. If keratitis is diagnosed, the benefits and risks of continuing treatment should be carefully considered.</p><p>Vectibix should be used with caution in patients with a history of keratitis, ulcerative keratitis or severe dry eye. Contact lens use is also a risk factor for keratitis and ulceration.</p><p>&nbsp;</p><p><u>Patients with ECOG 2 performance status treated with Vectibix in combination with chemotherapy</u></p><p>For patients with ECOG 2 performance status, assessment of benefit-risk is recommended prior to initiation of Vectibix in combination with chemotherapy for treatment of mCRC. A positive benefit‑risk balance has not been documented in patients with ECOG 2 performance status.</p><p>&nbsp;</p><p><u>Elderly patients</u></p><p>No overall differences in safety or efficacy were observed in elderly patients (&ge;&nbsp;65 years of age) treated with Vectibix monotherapy. However, an increased number of serious adverse reactions were reported in elderly patients treated with Vectibix in combination with FOLFIRI or FOLFOX chemotherapy compared to chemotherapy alone (see section 4.8).</p><p><u>Warnings for excipients</u></p><p>This medicinal product contains 3.45&nbsp;mg sodium per mL, equivalent to 0. 17% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Data from an interaction study involving Vectibix and irinotecan in patients with mCRC indicated that the pharmacokinetics of irinotecan and its active metabolite, SN-38, are not altered when the medicinal products are co-administered. Results from a cross-study comparison indicated that irinotecan-containing regimens (IFL or FOLFIRI) have no effect on the pharmacokinetics of panitumumab.</p><p>&nbsp;</p><p>Vectibix should not be administered in combination with IFL chemotherapy or with bevacizumab‑containing chemotherapy. A high incidence of severe diarrhoea was observed when panitumumab was administered in combination with IFL (see section 4.4), and increased toxicity and deaths were seen when panitumumab was combined with bevacizumab and chemotherapy (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>The combination of Vectibix with oxaliplatin-containing chemotherapy is contraindicated for patients with mutant <em>RAS</em> mCRC or for whom <em>RAS</em> mCRC status is unknown. A shortened progression-free survival and overall survival time were observed in a clinical study in patients with mutant <em>RAS</em> tumours who received panitumumab and FOLFOX (see sections 4.4 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate data from the use of Vectibix in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. EGFR has been implicated in the control of prenatal development and may be essential for normal organogenesis, proliferation, and differentiation in the developing embryo. Therefore, Vectibix has the potential to cause foetal harm when administered to pregnant women.</p><p>Human IgG is known to cross the placental barrier, and panitumumab may therefore be transmitted from the mother to the developing foetus. In women of childbearing potential, appropriate contraceptive measures must be used during treatment with Vectibix, and for 2&nbsp;months following the last dose. If Vectibix is used during pregnancy or if the patient becomes pregnant while receiving this medicinal product, she should be advised of the potential risk for loss of the pregnancy or potential hazard to the foetus.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether panitumumab is excreted in human breast milk. Because human IgG is secreted into human milk, panitumumab might also be secreted. The potential for absorption and harm to the infant after ingestion is unknown. It is recommended that women do not breast-feed during treatment with Vectibix and for 2&nbsp;months after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal studies have shown reversible effects on the menstrual cycle and reduced female fertility in monkeys (see section 5.3). Panitumumab may impact the ability of a woman to become pregnant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vectibix may have a minor influence on the ability to drive and use machines. If patients experience treatment-related symptoms affecting their vision and/or ability to concentrate and react, it is recommended that they do not drive or use machines until the effect subsides.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of safety profile</u></p><p>Based on an analysis of all mCRC clinical trial patients receiving Vectibix monotherapy and in combination with chemotherapy (n&nbsp;=&nbsp;2,224), the most commonly reported adverse reactions are skin reactions occurring in approximately 94% of patients. These reactions are related to the pharmacologic effects of Vectibix, and the majority are mild to moderate in nature with 23% severe (grade&nbsp;3 NCI‑CTC) and &lt;&nbsp;1% life-threatening (grade&nbsp;4 NCI-CTC). For clinical management of skin reactions, including dose modification recommendations, see section 4.4.</p><p>Very commonly reported adverse reactions occurring in &ge;&nbsp;20% of patients were gastrointestinal disorders [diarrhoea (46%), nausea (39%), vomiting (26%), constipation (23%) and abdominal pain (23%)]; general disorders [fatigue (35%), pyrexia (21%)]; metabolism and nutrition disorders [decreased appetite (30%)]; infections and infestations [paronychia (20%)]; and skin and subcutaneous disorders [rash (47%), dermatitis acneiform (39%), pruritus (36%), erythema (33%) and dry skin (21%)]. &nbsp;</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The data in the table below describe adverse reactions reported from clinical studies in patients with mCRC who received panitumumab as a single agent or in combination with chemotherapy (n&nbsp;=&nbsp;2,224) and spontaneous reporting. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p>Very common<br />(&ge;&nbsp;1/10)</p></td><td style="vertical-align:top"><p><strong>Common<br />(</strong><strong>&ge;&nbsp;1/100 to &lt;</strong>&nbsp;<strong>1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>(&ge;</strong>&nbsp;<strong>1/1000 to</strong></p><p><strong>&lt;</strong>&nbsp;<strong>1/100)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Conjunctivitis</p><p>Paronychia<sup>1</sup></p></td><td style="vertical-align:top"><p>Rash pustular</p><p>Cellulitis<sup>1</sup></p><p>Urinary tract infection</p><p>Folliculitis</p><p>Localised infection</p></td><td style="vertical-align:top"><p>Eye infection</p><p>Eyelid infection</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>Leucopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>1</sup></p></td><td style="vertical-align:top"><p>Anaphylactic reaction<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hypokalaemia</p><p>Hypomagnesaemia</p><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Hypocalcaemia</p><p>Dehydration</p><p>Hyperglycaemia</p><p>Hypophosphataemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blepharitis</p><p>Growth of eyelashes</p><p>Lacrimation increased</p><p>Ocular hyperaemia</p><p>Dry eye</p><p>Eye pruritus</p><p>Eye irritation</p></td><td style="vertical-align:top"><p>Ulcerative keratitis<sup>1,4</sup></p><p>Keratitis<sup>1</sup></p><p>Eyelid irritation</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Cyanosis</p><p><sup>&nbsp;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Deep vein thrombosis</p><p>Hypotension</p><p>Hypertension</p><p>Flushing</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Cough</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary embolism</p><p>Epistaxis</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial lung disease<sup>3</sup></p><p>Bronchospasm</p><p>Nasal dryness</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea<sup>1</sup></p><p>Nausea</p><p>Vomiting</p><p>Abdominal pain<s> </s></p><p>Stomatitis</p><p>Constipation</p></td><td style="vertical-align:top"><p>Rectal haemorrhage</p><p>Dry mouth</p><p>Dyspepsia</p><p>Aphthous ulcer</p><p>Cheilitis</p><p>Gastro-oesophageal reflux disease</p></td><td style="vertical-align:top"><p>Chapped lips</p><p>Dry lips</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders<sup>1</sup></p></td><td style="vertical-align:top"><p>Dermatitis acneiform</p><p>Rash</p><p>Erythema</p><p>Pruritus</p><p>Dry skin</p><p>Skin fissures</p><p>Acne</p><p>Alopecia</p></td><td style="vertical-align:top"><p>Skin ulcer</p><p>Skin exfoliation</p><p>Exfoliative rash</p><p>Dermatitis</p><p>Rash papular</p><p>Rash pruritic</p><p>Rash erythematous</p><p>Rash generalised</p><p>Rash macular</p><p>Rash maculo-papular</p><p>Skin lesion</p><p>Skin toxicity</p><p>Scab</p><p>Hypertrichosis</p><p>Onychoclasis</p><p>Nail disorder</p><p>Hyperhidrosis</p><p>Palmar-plantar erythrodysaesthesia syndrome</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis<sup>1,4</sup></p><p>Stevens-Johnson syndrome<sup>1,4</sup></p><p>Skin necrosis<sup>1,4</sup></p><p>Angioedema<sup>1</sup></p><p>Hirsutism</p><p>Ingrowing nail</p><p>Onycholysis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue</p><p>Pyrexia</p><p>Asthenia</p><p>Mucosal inflammation</p><p>Oedema peripheral</p></td><td style="vertical-align:top"><p>Chest pain</p><p>Pain</p><p>Chills</p><p><sup>&nbsp;</sup></p></td><td style="vertical-align:top"><p><sup>&nbsp;</sup></p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Infusion-related reaction<sup>1</sup></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Blood magnesium decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup> See section &ldquo;Description of selected adverse reactions&rdquo; below</p><p><sup>2</sup> See section 4.4 Infusion-related reactions</p><p><sup>3</sup> See section 4.4 Pulmonary complications</p><p>&nbsp;</p><p><sup>4</sup> Skin necrosis, Stevens-Johnson syndrome, toxic epidermal necrolysis and ulcerative keratitis are panitumumab ADRs that were reported in the post-marketing setting. For these ADRs the maximum frequency category was estimated from the upper limit of 95% confidence interval for the point estimate based on regulatory guidelines for estimation of the frequency of adverse reactions from spontaneous reporting. The maximum frequency estimated from the upper limit of 95% confidence interval for the point estimate, i.e., 3/2,224 (or 0.13%).</p><p>&nbsp;</p><p>The safety profile of Vectibix in combination with chemotherapy consisted of the reported adverse reactions of Vectibix (as a monotherapy) and the toxicities of the background chemotherapy regimen. No new toxicities or worsening of previously recognised toxicities beyond the expected additive effects were observed. Skin reactions were the most frequently occurring adverse reactions in patients receiving panitumumab in combination with chemotherapy. Other toxicities that were observed with a greater frequency relative to monotherapy included hypomagnesaemia, diarrhoea, and stomatitis. These toxicities infrequently led to discontinuation of Vectibix or of chemotherapy.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Gastrointestinal disorders</em></p><p>&nbsp;</p><p>Diarrhoea when reported was mainly mild or moderate in severity. Severe diarrhoea (NCI-CTC grade 3 and 4) was reported in 2% of patients treated with Vectibix as a monotherapy and in 16% of patients treated with Vectibix in combination with chemotherapy.</p><p>&nbsp;</p><p>There have been reports of acute renal failure in patients who develop diarrhoea and dehydration (see section 4.4).</p><p>&nbsp;</p><p><em>Infusion-related reactions</em></p><p>&nbsp;</p><p>Across monotherapy and combination mCRC clinical studies (n&nbsp;=&nbsp;2,224), infusion-related reactions (occurring within 24&nbsp;hours of any infusion), which may include symptoms/signs such as chills, fever or dyspnoea, were reported in approximately 5% of Vectibix-treated patients, of which 1% were severe (NCI-CTC grade 3 and grade 4).</p><p>&nbsp;</p><p>A case of fatal angioedema occurred in a patient with recurrent and metastatic squamous cell carcinoma of the head and neck treated with Vectibix in a clinical trial. The fatal event occurred after re-exposure following a prior episode of angioedema; both episodes occurred greater than 24&nbsp;hours after administration (see sections 4.3 and 4.4). Hypersensitivity reactions occurring more than 24&nbsp;hours after infusion have also been reported in the post-marketing setting.</p><p>&nbsp;</p><p>For clinical management of infusion-related reactions, see section 4.4.</p><p>&nbsp;</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>&nbsp;</p><p>Skin rash most commonly occurred on the face, upper chest, and back, but could extend to the extremities. Subsequent to the development of severe skin and subcutaneous reactions, infectious complications including sepsis, in rare cases leading to death, cellulitis and local abscesses requiring incisions and drainage were reported. The median time to first symptom of dermatologic reaction was 10&nbsp;days, and the median time to resolution after the last dose of Vectibix was 31&nbsp;days.</p><p>&nbsp;</p><p>Paronychial inflammation was associated with swelling of the lateral nail folds of the toes and fingers.</p><p>&nbsp;</p><p>Dermatological reactions (including nail effects), observed in patients treated with Vectibix or other EGFR inhibitors, are known to be associated with the pharmacologic effects of therapy.</p><p>&nbsp;</p><p>Across all clinical trials, skin reactions occurred in approximately 94% of patients receiving Vectibix as monotherapy or in combination with chemotherapy (n&nbsp;=&nbsp;2,224). These events consisted predominantly of rash and dermatitis acneiform and were&nbsp;mostly mild to moderate in severity. Severe (NCI-CTC grade 3) skin reactions were reported in 23% and life-threatening (NCI-CTC grade 4) skin reactions in &lt;&nbsp;1% of patients. In a randomized control trial, skin toxicity was severe (NCI-CTC</p><p>&nbsp;</p><p>grade&nbsp;3 and higher) in 15% of patients receiving Vectibix monotherapy (n = 229). Life-threatening and fatal infectious complications including necrotising fasciitis and sepsis have been observed in patients treated with Vectibix (see section 4.4).</p><p>&nbsp;</p><p>For clinical management of dermatological reactions, including dose modification recommendations, see section 4.4.</p><p><u>&nbsp;</u></p><p>In the post-marketing setting, rare cases of skin necrosis, Stevens-Johnson syndrome and toxic epidermal necrolysis (see section 4.4) have been reported.</p><p><em>&nbsp;</em></p><p><em>Ocular toxicities</em></p><p><u>&nbsp;</u></p><p>Serious cases of keratitis and ulcerative keratitis, which may lead to corneal perforation,have been reported (see section 4.4).</p><p>&nbsp;</p><p><u>Other special populations </u></p><p>&nbsp;</p><p>No overall differences in safety or efficacy were observed in elderly patients (&ge;&nbsp;65 years of age) treated with Vectibix monotherapy. However, an increased number of serious adverse events were reported in elderly patients treated with Vectibix in combination with FOLFIRI (45% versus 32%) or FOLFOX (52% versus 37%) chemotherapy compared to chemotherapy alone (see section 4.4). The most increased serious adverse events included diarrhoea in patients treated with Vectibix in combination with either FOLFOX or FOLFIRI, and dehydration and pulmonary embolism when patients were treated with Vectibix in combination with FOLFIRI.</p><p><strong>&nbsp;</strong></p><p>The safety of Vectibix has not been studied in patients with renal or hepatic impairment.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to their local representative.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><tbody><tr><td style="vertical-align:top"><p>To report any side effects:</p><p>Saudi Arabia:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses up to 9&nbsp;mg/kg have been tested in clinical trials. There have been reports of overdose at doses up to approximately twice the recommended therapeutic dose (12&nbsp;mg/kg). Adverse events observed included skin toxicity, diarrhoea, dehydration and fatigue and were consistent with the safety profile at the recommended dose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies, ATC code: L01XC08</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Panitumumab is a recombinant, fully human IgG2 monoclonal antibody that binds with high affinity and specificity to the human EGFR. EGFR is a transmembrane glycoprotein that is a member of a subfamily of type I receptor tyrosine kinases including EGFR (HER1/c-ErbB-1), HER2, HER3, and HER4. EGFR promotes cell growth in normal epithelial tissues, including the skin and hair follicle, and is expressed on a variety of tumour cells.</p><p>&nbsp;</p><p>Panitumumab binds to the ligand binding domain of EGFR and inhibits receptor autophosphorylation induced by all known EGFR ligands. Binding of panitumumab to EGFR results in internalisation of the receptor, inhibition of cell growth, induction of apoptosis, and decreased interleukin&nbsp;8 and vascular endothelial growth factor production.</p><p>&nbsp;</p><p><em>KRAS</em> (Kirsten rat sarcoma 2 viral oncogene homologue) and <em>NRAS </em>(Neuroblastoma <em>RAS</em> viral oncogene homologue) are highly related members of the <em>RAS</em> oncogene family. <em>KRAS</em> and <em>NRAS</em> genes encode small, GTP-binding proteins involved in signal transduction. A variety of stimuli, including that from the EGFR activate <em>KRAS</em> and <em>NRAS </em>which in turn stimulate other intracellular proteins to promote cell proliferation, cell survival and angiogenesis.</p><p>&nbsp;</p><p>Activating mutations in the <em>RAS</em> genes occur frequently in a variety of human tumours and have been implicated in both oncogenesis and tumour progression.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p><em>In vitro</em> assays and <em>in vivo</em> animal studies have shown that panitumumab inhibits the growth and survival of tumour cells expressing EGFR. No anti-tumour effects of panitumumab were observed in human tumour xenografts lacking EGFR expression. The addition of panitumumab to radiation, chemotherapy or other targeted therapeutic agents, in animal studies resulted in an increase in anti‑tumour effects compared to radiation, chemotherapy or targeted therapeutic agents alone.</p><p>&nbsp;</p><p>Dermatological reactions (including nail effects), observed in patients treated with Vectibix or other EGFR inhibitors, are known to be associated with the pharmacologic effects of therapy (with cross‑reference to sections 4.2 and 4.8).</p><p><u>&nbsp;</u></p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>As with all therapeutic proteins, there is potential for immunogenicity. Data on the development of anti-panitumumab antibodies has been evaluated using two different screening immunoassays for the detection of binding anti-panitumumab antibodies (an ELISA which detects high-affinity antibodies, and a Biosensor Immunoassay which detects both high and low-affinity antibodies). For patients whose sera tested positive in either screening immunoassay, an <em>in vitro</em> biological assay was performed to detect neutralising antibodies.</p><p>&nbsp;</p><p>As monotherapy:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The incidence of binding antibodies (excluding predose and transient positive patients) was &lt;&nbsp;1% as detected by the acid-dissociation ELISA and 3.8% as detected by the Biacore assay;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The incidence of neutralising antibodies (excluding predose and transient positive patients) was &lt;&nbsp;1%;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Compared with patients who did not develop antibodies, no relationship between the presence of anti-panitumumab antibodies and pharmacokinetics, efficacy and safety has been observed.</p><p>In combination with irinotecan- or oxaliplatin-based chemotherapy:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The incidence of binding antibodies (excluding predose positive patients) was 1% as detected by the acid-dissociation ELISA and &lt;&nbsp;1% as detected by the Biacore assay;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The incidence of neutralising antibodies (excluding predose positive patients) was &lt;&nbsp;1%;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No evidence of an altered safety profile was found in patients who tested positive for antibodies to Vectibix.</p><p>&nbsp;</p><p>The detection of antibody formation is dependent on the sensitivity and specificity of the assay. The observed incidence of antibody positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant &nbsp;medicinal products and underlying disease, therefore, comparison of the incidence of antibodies to other products may be misleading.</p><p><em>&nbsp;</em></p><p><u>Clinical efficacy as monotherapy</u></p><p>&nbsp;</p><p>The efficacy of Vectibix as monotherapy in patients with metastatic colorectal cancer (mCRC) who had disease progression during or after prior chemotherapy was studied in open-label, single-arm trials (585&nbsp;patients) and in two randomised controlled trials versus best supportive care (463&nbsp;patients) and versus cetuximab (1,010 patients).</p><p>&nbsp;</p><p>A multinational, randomised, controlled trial was conducted in 463&nbsp;patients with EGFR-expressing metastatic carcinoma of the colon or rectum after confirmed failure of oxaliplatin and irinotecan‑containing regimens. Patients were randomised 1:1 to receive Vectibix at a dose of 6&nbsp;mg/kg given once every two weeks plus best supportive care (not including chemotherapy) (BSC) or BSC alone. Patients were treated until disease progression or unacceptable toxicity occurred. Upon disease progression BSC alone patients were eligible to crossover to a companion study and receive Vectibix at a dose of 6&nbsp;mg/kg given once every two weeks.</p><p>&nbsp;</p><p>The primary endpoint was PFS. The study was retrospectively analysed by wild-type<em> KRAS </em>(exon 2) status versus mutant <em>KRAS </em>(exon 2) status. Tumour samples obtained from the primary resection of colorectal cancer were analysed for the presence of the seven most common activating mutations in the codon 12 and 13 of the <em>KRAS</em> gene. 427 (92%) patients were evaluable for <em>KRAS</em> status of which 184 had mutations. The efficacy results from an analysis adjusting for potential bias from unscheduled assessments are shown in the table below. There was no difference in overall survival (OS) seen in either group.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Wild</strong><strong>-type <em>KRAS</em> (exon 2) population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Mutant <em>KRAS </em>(exon 2)<em> </em>population</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Vectibix plus BSC </strong></p><p><strong>(n&nbsp;=&nbsp;124)</strong></p></td><td style="vertical-align:top"><p><strong>BSC</strong></p><p><strong>(n&nbsp;=&nbsp;119)</strong></p></td><td style="vertical-align:top"><p><strong>Vectibix plus BSC</strong></p><p><strong>(n&nbsp;=&nbsp;84)</strong></p></td><td style="vertical-align:top"><p><strong>BSC </strong></p><p><strong>(n&nbsp;=&nbsp;100)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>ORR n (%)</strong></p></td><td style="vertical-align:top"><p>17%</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td style="vertical-align:top"><p>Response rate (investigator</p><p>assessed)<sup>a</sup> (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>22%</p><p>(14,&nbsp;32)</p></td><td colspan="2" style="vertical-align:top"><p>0%</p><p>(0, 4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Stable Disease</strong></p></td><td style="vertical-align:top"><p>34%</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>12%</p></td><td style="vertical-align:top"><p>8%</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS</strong></p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.49 (0.37,0.65), p&nbsp;&lt;&nbsp;0.0001</p></td><td colspan="2" style="vertical-align:top"><p>1.07 (0.77,1.48), p&nbsp;=&nbsp;0.6880</p></td></tr><tr><td style="vertical-align:top"><p>Median (weeks)</p></td><td style="vertical-align:top"><p>16.0</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>8.0</p></td><td style="vertical-align:top"><p>8.0</p></td></tr></tbody></table><p>CI = confidence interval</p><p><sup>a</sup> In patients that crossed over to panitumumab after progression on BSC alone (95% CI)</p><p>&nbsp;</p><p>In an exploratory analysis of banked tumour specimens from this study, 11&nbsp;of 72&nbsp;patients (15%) with wild-type <em>RAS</em> tumours receiving panitumumab had an objective response compared to only 1 of 95&nbsp;patients (1%) with mutant <em>RAS</em> tumour status. Moreover, panitumumab treatment was associated with improved PFS compared to BSC in patients with wild-type <em>RAS</em> tumours (HR&nbsp;=&nbsp;0.38 [95% CI: 0.27, 0.56]), but not in patients with tumours harbouring a <em>RAS</em> mutation (HR&nbsp;=&nbsp;0.98 [95% CI: 0.73, 1.31]).</p><p>&nbsp;</p><p>The efficacy of Vectibix was also evaluated in an open-label trial&nbsp;in patients with&nbsp;wild-type <em>KRAS</em> (exon 2) mCRC. A total of 1,010 patients&nbsp;refractory to chemotherapy&nbsp;were randomised&nbsp;1:1 to receive Vectibix or cetuximab&nbsp;to test whether Vectibix is non-inferior to cetuximab. The primary endpoint was&nbsp;OS. Secondary endpoints included PFS and objective response rate (ORR).&nbsp;&nbsp;</p><p>&nbsp;</p><p>The efficacy results for the study are presented in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:95%"><thead><tr><td><p><strong>Wild-type <em>KRAS</em> (exon 2) population</strong></p></td><td><p><strong>Vectibix </strong></p><p>(n&nbsp;=&nbsp;499)</p></td><td><p><strong>Cetuximab</strong></p><p>&nbsp;(n&nbsp;=&nbsp;500)</p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td><p>10.4 (9.4, 11.6)</p></td><td><p>10.0 (9.3, 11.0)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2"><p>0.97 (0.84, 1.11)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td><p>4.1 (3.2, 4.8)</p></td><td><p>4.4 (3.2, 4.8)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)</p></td><td colspan="2"><p>1.00 (0.88, 1.14)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ORR</strong></p></td></tr><tr><td style="vertical-align:top"><p>n (%) (95% CI)</p></td><td><p>22% (18%, 26%)</p></td><td style="vertical-align:top"><p>20% (16%, 24%)</p></td></tr><tr><td style="vertical-align:top"><p>Odds ratio (95% CI)</p></td><td colspan="2"><p>1.15 (0.83, 1.58)</p></td></tr></tbody></table><p>&nbsp;</p><p>Overall, the safety profile of panitumumab was similar to that of cetuximab, in particular regarding skin toxicity. However, infusion reactions were more frequent with cetuximab (13% versus 3%) but electrolyte disturbances were more frequent with panitumumab, especially hypomagnesaemia (29% versus 19%).</p><p>&nbsp;</p><p><u>Clinical efficacy in combination with chemotherapy</u></p><p>&nbsp;</p><p>Among patients with wild-type <em>RAS</em> mCRC, PFS, OS, and ORR were improved for subjects receiving panitumumab plus chemotherapy (FOLFOX or FOLFIRI) compared with those receiving chemotherapy alone. Patients with additional <em>RAS</em> mutations beyond <em>KRAS</em> exon 2 were unlikely to benefit from the addition of panitumumab to FOLFIRI and a detrimental effect was seen with the addition of panitumumab to FOLFOX in these patients. <em>BRAF</em> mutations in exon 15 were found to be prognostic of worse outcome. <em>BRAF</em> mutations were not predictive of the outcome for panitumumab treatment in combination with FOLFOX or FOLFIRI.</p><p>&nbsp;</p><p><em><u>First-line combination with FOLFOX</u></em></p><p>&nbsp;</p><p>The efficacy of Vectibix in combination with oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (FOLFOX) was evaluated in a randomised, controlled trial of 1,183 patients with mCRC with the primary endpoint of PFS. Other key endpoints included the OS, ORR, time to response, time to progression (TTP), and duration of response. The study was prospectively analysed by tumour <em>KRAS </em>(exon 2) status which was evaluable in 93% of the patients.</p><p>&nbsp;</p><p>A predefined retrospective subset analysis of 641 patients of the 656 patients with wild-type <em>KRAS </em>(exon 2) mCRC was performed. Patient tumour samples with wild-type <em>KRAS</em> exon&nbsp;2 (codons&nbsp;12/13) status were tested for additional <em>RAS </em>mutations in <em>KRAS</em> exon&nbsp;3 (codons&nbsp;61) and exon&nbsp;4 (codons&nbsp;117/146) and <em>NRAS </em>exon&nbsp;2 (codons&nbsp;12/13), exon&nbsp;3 (codon&nbsp;61), and exon&nbsp;4 (codons&nbsp;117/146) and <em>BRAF </em>exon 15 (codon 600). The incidence of these additional <em>RAS</em> mutations in the wild-type <em>KRAS</em> exon&nbsp;2 population was approximately 16%.</p><p>&nbsp;</p><p>Results in patients with wild-type <em>RAS</em> mCRC and mutant <em>RAS</em> mCRC are presented in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Vectibix plus FOLFOX</strong></p><p><strong>(months)</strong></p><p><strong>Median (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>FOLFOX</strong></p><p><strong>(months)</strong></p><p><strong>&nbsp;Median (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Difference (months)</strong></p></td><td style="vertical-align:top"><p><strong>Hazard ratio<br />(95% CI)</strong></p></td></tr></thead><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Wild-type <em>RAS</em> population</strong></p></td></tr><tr><td style="vertical-align:top"><p>PFS</p></td><td style="vertical-align:top"><p>10.1</p><p>(9.3, 12.0)</p></td><td style="vertical-align:top"><p>7.9</p><p>(7.2, 9.3)</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.72</p><p>(0.58, 0.90)</p></td></tr><tr><td style="vertical-align:top"><p>OS</p></td><td style="vertical-align:top"><p>26.0</p><p>(21.7, 30.4)</p></td><td style="vertical-align:top"><p>20.2</p><p>(17.7, 23.1)</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>0.78</p><p>(0.62, 0.99)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Mutant <em>RAS</em> population</strong></p></td></tr><tr><td style="vertical-align:top"><p>PFS</p></td><td style="vertical-align:top"><p>7.3</p><p>(6.3, 7.9)</p></td><td style="vertical-align:top"><p>8.7</p><p>(7.6, 9.4)</p></td><td style="vertical-align:top"><p>-1.4</p></td><td style="vertical-align:top"><p>1.31</p><p>(1.07, 1.60)</p></td></tr><tr><td style="vertical-align:top"><p>OS</p></td><td style="vertical-align:top"><p>15.6</p><p>(13.4, 17.9)</p></td><td style="vertical-align:top"><p>19.2</p><p>(16.7, 21.8)</p></td><td style="vertical-align:top"><p>-3.6</p></td><td style="vertical-align:top"><p>1.25</p><p>(1.02, 1.55)</p></td></tr></tbody></table><p>&nbsp;</p><p>Additional mutations in <em>KRAS</em> and <em>NRAS</em> at exon 3 (codon 59) were subsequently identified (n&nbsp;=&nbsp;7). An exploratory analysis showed similar results to those in the previous table.</p><p>&nbsp;</p><p><em><u>Combination with FOLFIRI</u></em></p><p>&nbsp;</p><p>The efficacy of Vectibix in second-line in combination with irinotecan, 5-fluorouracil (5-FU) and leucovorin (FOLFIRI) was evaluated in a randomised, controlled trial of 1,186&nbsp;patients with mCRC with the primary endpoints of OS and PFS. Other key endpoints included the ORR, time to response, TTP, and duration of response. The study was prospectively analysed by tumour <em>KRAS </em>(exon 2) status which was evaluable in 91% of the patients.</p><p>&nbsp;</p><p>A predefined retrospective subset analysis of 586 patients of the 597 patients with wild-type <em>KRAS</em> (exon 2) mCRC was performed, where tumour samples from these patients<s> </s>were tested for additional <em>RAS </em>and<em> BRAF </em>mutations as previously described. The <em>RAS/BRAF</em> ascertainment was 85% (1,014 of 1,186 randomised patients). The incidence of these additional <em>RAS</em> mutations (<em>KRAS</em> exons 3, 4 and <em>NRAS</em> exons 2, 3, 4) in the wild-type <em>KRAS</em> (exon 2) population was approximately 19%. The incidence of <em>BRAF</em> exon 15 mutation in the wild-type <em>KRAS</em> (exon 2) population was approximately 8%. Efficacy results in patients with wild-type <em>RAS</em> mCRC and mutant <em>RAS</em> mCRC are shown in the below table.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Vectibix plus FOLFIRI</strong></p><p><strong>(months)</strong></p><p><strong>Median (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>FOLFIRI</strong></p><p><strong>(months)</strong></p><p><strong>&nbsp;Median (95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>Hazard ratio<br />(95% CI)</strong></p></td></tr></thead><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Wild-type <em>RAS</em> population</strong></p></td></tr><tr><td style="vertical-align:top"><p>PFS</p></td><td style="vertical-align:top"><p>6.4</p><p>(5.5, 7.4)</p></td><td style="vertical-align:top"><p>4.6</p><p>(3.7, 5.6)</p></td><td style="vertical-align:top"><p>0.70</p><p>(0.54, 0.91)</p></td></tr><tr><td style="vertical-align:top"><p>OS</p></td><td style="vertical-align:top"><p>16.2</p><p>(14.5, 19.7)</p></td><td style="vertical-align:top"><p>13.9 (11.9, 16.0)</p></td><td style="vertical-align:top"><p>0.81</p><p>(0.63, 1.02)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Mutant <em>RAS</em> population</strong></p></td></tr><tr><td style="vertical-align:top"><p>PFS</p></td><td style="vertical-align:top"><p>4.8</p><p>(3.7, 5.5)</p></td><td style="vertical-align:top"><p>4.0</p><p>(3.6, 5.5)</p></td><td style="vertical-align:top"><p>0.86</p><p>(0.70, 1.05)</p></td></tr><tr><td style="vertical-align:top"><p>OS</p></td><td style="vertical-align:top"><p>11.8</p><p>(10.4, 13.1)</p></td><td style="vertical-align:top"><p>11.1</p><p>(10.2, 12.4)</p></td><td style="vertical-align:top"><p>0.91</p><p>(0.76, 1.10)</p></td></tr></tbody></table><p>&nbsp;</p><p>The efficacy of Vectibix in first-line in combination with FOLFIRI was evaluated in a single-arm study of 154 patients with the primary endpoint of objective response rate (ORR). Other key endpoints included the PFS, time to response, TTP, and duration of response.</p><p>&nbsp;</p><p>A predefined retrospective subset analysis of 143 patients of the 154 patients with wild-type <em>KRAS</em> (exon 2) mCRC was performed, where tumour samples from these patients were tested for additional <em>RAS</em> mutations. The incidence of these additional <em>RAS</em> mutations (<em>KRAS </em>exons 3, 4 and <em>NRAS</em> exons 2, 3, 4) in the wild-type <em>KRAS</em> (exon&nbsp;2) population was approximately 10%.</p><p>&nbsp;</p><p>Results in patients with wild-type <em>RAS</em> mCRC and mutant <em>RAS</em> mCRC from the primary analysis are presented in the table below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Panitumumab + FOLFIRI</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Wild-type <em>RAS</em> </strong><strong>(n&nbsp;=&nbsp;69)</strong></p></td><td style="vertical-align:top"><p><strong>Mutant <em>RAS </em></strong><strong>(n&nbsp;=&nbsp;74)</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR (%)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>59</p><p>(46, 71)</p></td><td style="vertical-align:top"><p>41</p><p>(30, 53)</p></td></tr><tr><td style="vertical-align:top"><p>Median PFS (months)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>11.2</p><p>(7.6, 14.8)</p></td><td style="vertical-align:top"><p>7.3</p><p>(5.8, 7.5)</p></td></tr><tr><td style="vertical-align:top"><p>Median Duration of response (months)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>13.0</p><p>(9.3, 15.7)</p></td><td style="vertical-align:top"><p>5.8</p><p>(3.9, 7.8)</p></td></tr><tr><td style="vertical-align:top"><p>Median TTP (months)</p><p>(95% CI)</p></td><td style="vertical-align:top"><p>13.2</p><p>(7.8, 17.0)</p></td><td style="vertical-align:top"><p>7.3</p><p>(6.1, 7.6)</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>First-line combination with bevacizumab and oxaliplatin or irinotecan-based chemotherapy</u></em></p><p><strong><u>&nbsp;</u></strong></p><p>In a randomised, open-label, controlled clinical trial, chemotherapy (oxaliplatin or irinotecan) and bevacizumab were given with and without panitumumab in the first-line treatment of patients with metastatic colorectal cancer (n&nbsp;=&nbsp;1,053 [n&nbsp;=&nbsp;823 oxaliplatin cohort, n&nbsp;=&nbsp;230 irinotecan cohort]). Panitumumab treatment was discontinued due to a statistically significant reduction in PFS in patients receiving panitumumab observed in an interim analysis.</p><p>&nbsp;</p><p>The major study objective was comparison of PFS in the oxaliplatin cohort. In the final analysis, the hazard ratio for PFS was 1.27 (95% CI: 1.06, 1.52). Median PFS was 10.0 (95%&nbsp;CI:&nbsp;8.9,&nbsp;11.0) and 11.4 (95% CI: 10.5, 11.9) months in the panitumumab and the non-panitumumab arm, respectively. There was an increase in mortality in the panitumumab arm. The hazard ratio for overall survival was 1.43 (95% CI: 1.11, 1.83). Median OS was 19.4 (95% CI: 18.4, 20.8) and 24.5 (95% CI: 20.4, 24.5) in the panitumumab arm and the non-panitumumab arm.</p><p>&nbsp;</p><p>An additional analysis of efficacy data by <em>KRAS</em> (exon 2) status did not identify a subset of patients who benefited from panitumumab in combination with oxaliplatin- or irinotecan based chemotherapy and bevacizumab. For the wild-type <em>KRAS</em> subset of the oxaliplatin cohort, the hazard ratio for PFS was 1.36 with 95% CI: 1.04-1.77. For the mutant <em>KRAS</em> subset, the hazard ratio for PFS was 1.25 with 95% CI: 0.91-1.71. A trend for OS favouring the control arm was observed in the wild-type <em>KRAS</em> subset of the oxaliplatin cohort (hazard ratio&nbsp;=&nbsp;1.89; 95% CI: 1.30, 2.75). A trend towards worse survival was also observed with panitumumab in the irinotecan cohort regardless of <em>KRAS</em> mutational status. Overall, panitumumab treatment combined with chemotherapy and bevacizumab is associated with an unfavourable benefit-to-risk profile irrespective of tumour <em>KRAS</em> mutational status.</p><p>&nbsp;</p><p><u>Paediatric population </u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Vectibix in all subsets of the paediatric population in colorectal cancer (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vectibix administered as a single agent or in combination with chemotherapy exhibits nonlinear pharmacokinetics.</p><p>&nbsp;</p><p>Following a single-dose administration of panitumumab as a 1-hour infusion, the area under the concentration-time curve (AUC) increased in a greater than dose-proportional manner and clearance (CL) of panitumumab decreased from 30.6 to 4.6&nbsp;mL/day/kg as the dose increased from 0.75 to 9&nbsp;mg/kg. However, at doses above 2&nbsp;mg/kg, the AUC of panitumumab increases in an approximately dose-proportional manner.</p><p>&nbsp;</p><p>Following the recommended dose regimen (6&nbsp;mg/kg given once every 2&nbsp;weeks as a 1-hour infusion), panitumumab concentrations reached steady-state levels by the third infusion with mean (&plusmn; Standard Deviation [SD]) peak and trough concentrations of 213 &plusmn; 59 and 39 &plusmn; 14&nbsp;mcg/mL, respectively. The mean (&plusmn; SD) AUC0-tau and CL were 1,306 &plusmn; 374&nbsp;mcg&bull;day/mL and 4.9 &plusmn; 1.4&nbsp;mL/kg/day, respectively. The elimination half-life was approximately 7.5 days (range: 3.6 to 10.9 days).</p><p>&nbsp;</p><p>A population pharmacokinetic analysis was performed to explore the potential effects of selected covariates on panitumumab pharmacokinetics. Results suggest that age (21-88), gender, race, hepatic function, renal function, chemotherapeutic agents, and EGFR membrane staining intensity (1+, 2+, 3+) in tumour cells had no apparent impact on the pharmacokinetics of panitumumab.</p><p>&nbsp;</p><p>No clinical studies have been conducted to examine the pharmacokinetics of panitumumab in patients with renal or hepatic impairment.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:</p><p>&nbsp;</p><p>Skin rash and diarrhoea were the major findings observed in repeat-dose toxicity studies of up to 26&nbsp;weeks duration in cynomolgus monkeys. These findings were observed at doses approximately equivalent to the recommended human dose and were reversible upon termination of administration of panitumumab. The skin rash and diarrhoea observed in monkeys are considered related to the pharmacological action of panitumumab and are consistent with the toxicities observed with other anti-EGFR inhibitors.</p><p>&nbsp;</p><p>Studies to evaluate the mutagenic and carcinogenic potential of panitumumab have not been performed.</p><p>&nbsp;</p><p>Animal studies are insufficient with respect to embryo-foetal development since foetal panitumumab exposure levels were not examined. Panitumumab has been shown to cause foetal abortions and/or foetal deaths in cynomolgus monkeys when administered during the period of organogenesis at doses approximately equivalent to the recommended human dose.</p><p>&nbsp;</p><p>Formal male fertility studies have not been conducted; however, microscopic evaluation of male reproductive organs from repeat-dose toxicity studies in cynomolgus monkeys at doses up to approximately 5-fold the human dose on a mg/kg basis, revealed no differences compared to control male monkeys. Fertility studies conducted in female cynomolgus monkeys showed that panitumumab may produce prolonged menstrual cycle and/or amenorrhoea and reduced pregnancy rate which occurred at all doses evaluated.</p><p>&nbsp;</p><p>No pre- and post-natal development animal studies have been conducted with panitumumab. All patients should be advised regarding the potential risk of panitumumab on pre- and post-natal development prior to initiation of Vectibix therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each 5&nbsp;mL contains:</p><p>Sodium chloride: 29&nbsp;mg &nbsp;</p><p>Sodium acetate trihydrate: 34&nbsp;mg</p><p>Acetic acid, glacial (for pH-adjustment): As required<sup>b</sup></p><p>Water for injections: qs.</p><p>&nbsp;</p><p>Each 20&nbsp;mL contains:</p><p>Sodium chloride: 117&nbsp;mg &nbsp;</p><p>Sodium acetate trihydrate: 136&nbsp;mg</p><p>Acetic acid, glacial (for pH-adjustment): As required<sup>b</sup></p><p>Water for injections: qs.</p><p>&nbsp;</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Acetic acid is used to adjust pH to target of 5.8</p><p>qs&nbsp;&nbsp; quantum sufficit</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vial

3 years.

Diluted solution

Vectibix does not contain any antimicrobial preservative or bacteriostatic agent. The product should be used immediately after dilution. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should be no longer than 24 hours at 2°C - 8°C. The diluted solution must not be frozen.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;&ndash;&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass vial with an elastomeric stopper, aluminium seal and flip-off plastic cap.</p><p>One vial contains either 100&nbsp;mg of panitumumab in 5&nbsp;mL, or 400&nbsp;mg panitumumab in 20&nbsp;mL of concentrate for solution for infusion.</p><p>&nbsp;</p><p>Pack of 1 vial.</p><p>&nbsp;</p><p>Not all presentations may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vectibix is intended for single use only. Vectibix should be diluted in sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection by healthcare professional using aseptic technique. <u>Do not shake or vigorously agitate the vial</u>.&nbsp;Vectibix should be inspected visually prior to administration. The solution should be colourless and may contain visible translucent-to-white, amorphous, proteinaceous particulates (which will be removed by in-line filtration). Do not administer Vectibix if its appearance is not as described above. Using only a 21-gauge or smaller diameter hypodermic needle, withdraw the necessary amount of Vectibix for a dose of 6&nbsp;mg/kg. Do not use needle-free devices (e.g. vial adapters) to withdraw vial contents. Dilute in a total volume of 100&nbsp;mL. The final concentration should not exceed 10&nbsp;mg/mL. Doses higher than 1,000&nbsp;mg should be diluted in 150&nbsp;mL sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection (see section 4.2). The diluted solution should be mixed by gentle inversion, do not shake.</p><p>&nbsp;</p><p>Vectibix must be administered using a low protein binding 0.2 or 0.22&nbsp;micrometre in‑line filter, through a peripheral line or indwelling catheter.</p><p>&nbsp;</p><p>No incompatibilities have been observed between Vectibix and sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection in polyvinyl chloride bags or polyolefin bags.</p><p>&nbsp;</p><p>Discard the vial and any liquid remaining in the vial after the single-use.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amgen Europe B.V.
Minervum 7061
4817 ZK Breda
The Netherlands

MARKETING AUTHORISATION NUMBER(S) 

EU/1/07/423/001
EU/1/07/423/003

DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 3 December 2007
Date of latest renewal: 23 September 2019


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2021

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>